These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 15542374)

  • 1. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
    De Groot AS; Bishop EA; Khan B; Lally M; Marcon L; Franco J; Mayer KH; Carpenter CC; Martin W
    Methods; 2004 Dec; 34(4):476-87. PubMed ID: 15542374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV vaccine development by computer assisted design: the GAIA vaccine.
    De Groot AS; Marcon L; Bishop EA; Rivera D; Kutzler M; Weiner DB; Martin W
    Vaccine; 2005 Mar; 23(17-18):2136-48. PubMed ID: 15755584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.
    Fonseca SG; Coutinho-Silva A; Fonseca LA; Segurado AC; Moraes SL; Rodrigues H; Hammer J; Kallás EG; Sidney J; Sette A; Kalil J; Cunha-Neto E
    AIDS; 2006 Nov; 20(18):2263-73. PubMed ID: 17117012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct.
    Cardinaud S; Bouziat R; Rohrlich PS; Tourdot S; Weiss L; Langlade-Demoyen P; Burgevin A; Fiorentino S; van Endert P; Lemonnier FA
    AIDS; 2009 Sep; 23(15):1945-54. PubMed ID: 19644347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG
    Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.
    Geels MJ; Dubey SA; Anderson K; Baan E; Bakker M; Pollakis G; Paxton WA; Shiver JW; Goudsmit J
    J Virol; 2005 Sep; 79(17):11247-58. PubMed ID: 16103177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.
    Lekutis C; Shiver JW; Liu MA; Letvin NL
    J Immunol; 1997 May; 158(9):4471-7. PubMed ID: 9127013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
    Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach.
    De Groot AS; Jesdale B; Martin W; Saint Aubin C; Sbai H; Bosma A; Lieberman J; Skowron G; Mansourati F; Mayer KH
    Vaccine; 2003 Oct; 21(27-30):4486-504. PubMed ID: 14505932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
    Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
    J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island.
    Koita OA; Dabitao D; Mahamadou I; Tall M; Dao S; Tounkara A; Guiteye H; Noumsi C; Thiero O; Kone M; Rivera D; McMurry JA; Martin W; De Groot AS
    Hum Vaccin; 2006; 2(3):119-28. PubMed ID: 17012903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 envelope-specific CD4+ T helper cells from simian/human immunodeficiency virus-infected rhesus monkeys recognize epitopes restricted by MHC class II DRB1*0406 and DRB*W201 molecules.
    Lekutis C; Letvin NL
    J Immunol; 1997 Aug; 159(4):2049-57. PubMed ID: 9257873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA; Oka S; Takiguchi M
    Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.
    Zhan X; Slobod KS; Surman S; Brown SA; Coleclough C; Hurwitz JL
    Vaccine; 2004 Mar; 22(9-10):1206-13. PubMed ID: 15003649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.